Colorectal Cancer Clinical Trials 2024

What are the top hospitals conducting colorectal cancer research?

Colorectal cancer, a formidable adversary in the world of oncology, is being met head-on by some of the top hospitals in the United States. Leading the charge is Memorial Sloan Kettering Cancer Center in New york City, renowned for its cutting-edge research and patient care. With 12 active colorectal cancer trials and an impressive history of 70 trials dedicated to this disease, their commitment spans over three decades since recording their first trial back in 1989.

Heading south to Houston, we find M D Anderson Cancer Center making significant strides against colorectal cancer with nine ongoing clinical trials and a commendable track record of 49 completed studies. This prestigious institution recorded its first colorectal cancer trial in 2001, showcasing their dedication to combating this condition.

Back on the East Coast lies Massachusetts General Hospital in Boston—a powerhouse when it comes to medical advancements. They are currently conducting eight active colorectal cancer trials while having accomplished an extraordinary total of 71 previous investigations since initiating their inaugural trial also in 2001.

In Atlanta's Emory University Hospital/Winship Cancer Institute, researchers are dedicating themselves to pushing boundaries with seven ongoing clinical trials focused on colorectal cancer. Although they may have fewer all-time trials compared to others on this list (15), they have made remarkable progress since recording their first colorectal cancer trial as recently as 2012.

Last but certainly not least is Duke University Medical Center located within Durham—their contributions should not be underestimated. Currently engaged in six active clinical trials for colorectal cancer treatment options and having completed thirty-three prior investigations dating back from their initial pioneering study recorded backin2003;their work plays a vital role alongside other leading institutions across the nation.

These top-tier hospitals continue to wage war against colorectal cancers through rigorous research efforts and innovative treatments that bring hope to patients battling this disease worldwide. Their collective determination guides us toward brighter futures where improved outcomes become a reality for all those affected by colorectal cancer.

Which are the best cities for colorectal cancer clinical trials?

When it comes to colorectal cancer clinical trials, several cities have emerged as leading hubs for research. Los Angeles, California has 41 active trials focusing on treatment options like Eflornithine plus sulindac and Nivolumab. Boston, Massachusetts follows closely behind with 34 ongoing studies investigating treatments such as Radiation Therapy and JDQ443+trametinib. New york, New York also plays a significant role in colorectal cancer research with 30 active trials exploring treatment options like Pembrolizumab and pralsetinib (BLU-667). Houston, Texas and Atlanta, Georgia offer their own contributions to the field with 27 and 21 active trials respectively. These cities provide individuals facing colorectal cancer access to cutting-edge clinical trials that may revolutionize treatment approaches and improve outcomes.

Which are the top treatments for colorectal cancer being explored in clinical trials?

Colorectal cancer research is making significant strides, with a focus on several promising treatments currently being explored in clinical trials. Leading the pack is pembrolizumab, which has garnered attention in four active trials and 56 all-time colorectal cancer studies since its first listing in 2013. Another contender worth noting is nivolumab, involved in three ongoing trials and boasting an impressive track record of 39 all-time colorectal cancer studies since its introduction in 2014. Additionally, capecitabine deserves recognition for its two active trials and participation in a remarkable 111 all-time colorectal cancer studies since it was listed back in 2001. The progress made through these clinical trials offers renewed hope to patients battling this challenging disease each day.

What are the most recent clinical trials for colorectal cancer?

Exciting advancements are being made in the field of colorectal cancer research, with several recent clinical trials offering hope for improved treatment options. A2530 is currently undergoing Phase 1 and Phase 2 trials, demonstrating its potential to tackle this form of cancer. NUFIRI-bev on a Q1W NUC-3373 schedule is also being investigated in Phase 2 studies as a potential therapy option. Another promising trial involves botensilimab and balstilimab (bot/bal), which has entered Phase 2 testing for colorectal cancer patients. Additionally, SGN-BB228 showcases promise based on its ongoing Phase 1 trial results. Finally, tucatinib's efficacy as a treatment for colorectal cancer is under evaluation through its participation in a large-scale Phase 3 study initiated last year. These collective efforts signify significant progress towards improving outcomes for individuals affected by colorectal cancer.

What colorectal cancer clinical trials were recently completed?

Several notable clinical trials for colorectal cancer have recently concluded, demonstrating significant progress in the field. In January 2022, a trial by Mayo Clinic investigated the potential of Colorectal Cancer Peptide Vaccine PolyPEPI1018. Following closely behind is a trial conducted by Janssen Research & Development and completed in November 2021, which examined JNJ-64251330 therapy. Notably, Apros Therapeutics' APR003 study reached completion in January 2021. These recent advancements highlight the ongoing efforts to enhance treatment options for patients affected by colorectal cancer.